- Our current focus is on developing improved bone morphogenetic proteins (BMPs), which are important in bone and cartilage healing but current BMPs require high dosages, causing local and systemic side effects.

- Darnatein DA-BMPs are engineered for enhanced therapy, reducing required doses and minimizing the likelihood of adverse events.
- Darnatein’s lead DA biologics are made to be injected directly into affected tissues to promote regeneration of bone or cartilage, with the goal of restoring functionality and reducing pain.

- Darnatein is advancing two therapeutic candidates: DRT-101 – preclinical-stage asset for osteoarthritis – and DRT-102 – early clinical-stage asset for spinal fusion.